BASF SE

BASF is the world's largest chemical company by sales, built on the Verbund principle of physically and energetically integrated production sites that turn a handful of feedstocks into thousands of products. Since September 2024 it has run under the "Winning Ways" strategy, which splits the portfolio into four core segments (Chemicals, Materials, Industrial Solutions, Nutrition & Care) that stay integrated, and standalone businesses (Agricultural Solutions, Battery Materials, Environmental Catalyst and Metal Solutions, and the now-divested Coatings) that are being monetized or prepared for capital-market options. In 2025 it generated €59.7 billion in sales and €6.6 billion in EBITDA before special items, a cyclical trough. In 2026 it closed the €7.7 billion Coatings transaction, started up its €-multi-billion Zhanjiang Verbund site, raised earnings guidance, and approached Evonik about a takeover. The investment debate is whether structural cost cuts and portfolio proceeds can restore returns above the cost of capital.

---

The company's own description. BASF describes its purpose with the line "we create chemistry for a sustainable future" (BASF news release boilerplate, 2026) and states its ambition to be the preferred chemical company for enabling customers' green transformation. It reports around 108,000 employees, customers in nearly every sector and almost every country, and sales of around €60 billion in 2025. The portfolio is described as four core segments plus standalone businesses bundled in Surface Technologies and Agricultural Solutions.

Independent characterization. BASF is best understood as three businesses under one roof:

1. An integrated commodity and intermediates engine (Chemicals, the Monomers half of Materials). This is a steam-cracker-to-derivatives chain selling ethylene and propylene derivatives, isocyanates, polyamide precursors and intermediates on spread economics. Earnings are driven by feedstock and energy costs, operating rates and regional supply-demand. It is the most capital-intensive part of the group and the main source of the 2023–2025 earnings decline: Chemicals EBITDA before special items fell from €1,342 million in 2024 to €853 million in 2025 (Factsheet FY2025).

2. Formulated and performance products (Performance Materials, Industrial Solutions, Nutrition & Care). These sell on specification and performance to automotive, construction, packaging, consumer goods, pharma and nutrition customers. Margins are steadier but have come under pressure from Asian competition and, in Care Chemicals, from consumer trading-down to private-label products (Factsheet FY2025 commentary).

3. Standalone franchises with different industry logic: Agricultural Solutions (crop protection, seeds and traits, digital farming), ECMS (emissions catalysts plus precious-metal trading and recycling) and Battery Materials. Agricultural Solutions is the group's highest-margin segment at 21.7% EBITDA margin before special items in FY2025 and the largest single earnings contributor at €2,081 million.

Revenue model. Revenue is almost entirely product sales under supply contracts and spot transactions. There is no subscription model of consequence; digital farming (xarvio) and licensing of process technology and catalysts are small. Seeds and traits include royalty and licensing income within Agricultural Solutions, not separately disclosed. Precious-metal trading inflates ECMS sales (€7,978 million in FY2025) with pass-through metal value, which is why BASF quotes group margins both including and excluding metals (12.3% excluding metals in FY2025 per the CFO on the February 27, 2026 call, versus 11.0% reported).

Value chain position. Upstream to midstream in petrochemicals with captive crackers at Ludwigshafen, Antwerp, Port Arthur (joint venture with TotalEnergies), Nanjing (joint venture with Sinopec) and Zhanjiang; midstream to downstream in engineering plastics, polyurethane systems, dispersions, additives, surfactants and vitamins; branded and channel-driven in agriculture. BASF exited upstream oil and gas operations when Wintershall Dea's E&P business was transferred to Harbour Energy in September 2024.

Customers and end-markets. BASF serves industrial customers in chemicals and plastics, transportation, construction, consumer goods, agriculture, electronics, energy and resources, and health and nutrition. Intersegment transfers are large (Chemicals transferred €3,432 million internally in FY2025 on €10,055 million of third-party sales), which shows how much of the upstream output feeds BASF's own downstream chains.

Stated strategy. "Winning Ways" was presented at the Capital Markets Day on September 26–27, 2024. Its themes, paraphrased from BASF's reports and releases:

Focus: Run the four core segments as an integrated Verbund and treat Agricultural Solutions, Coatings, Battery Materials and ECMS as standalone businesses with their own industry-specific setups.

Accelerate: Unlock the value of the standalone businesses through sales, partnerships or listings.

Transform: Make BASF the preferred partner for customers' green transformation, and change the culture toward ownership and speed.

Win: Deliver on financial targets and shareholder distributions.

Initiatives announced or advanced in the last 24 months.

2026 guidance.

Next strategic event. Capital Markets Day on November 24, 2026, where all four members of the Agricultural Solutions Management Board will present (BASF release on the IPO bank mandate, September 2026).

BASF sells tens of thousands of products; it does not publish list prices, and pricing is contract or spot based unless noted. The catalog below is organized by segment and division.

Chemicals — Petrochemicals

Chemicals — Intermediates

Materials — Performance Materials

Materials — Monomers

Industrial Solutions — Dispersions & Resins

Industrial Solutions — Performance Chemicals

Nutrition & Care — Care Chemicals

Nutrition & Care — Nutrition & Health

Surface Technologies

Agricultural Solutions

Product mix by first-half 2026 sales: herbicides 32%, fungicides 30%, seeds and traits 23%, insecticides 10%, seed treatment 5% (BASF Q2 2026 presentation as reported by Investing.com, July 29, 2026).

Management quantified the peak sales potential of the agricultural innovation pipeline at €7.5 billion at the April 30, 2026 AGM.

Sources: BASF Report 2025 ten-year summary, statement of income and balance sheet; Factsheet FY2025; BASF Reports 2021–2024 for earlier years. FY2024 income-statement lines are restated.

Income statement

BASF has no material dilutive instruments; diluted EPS is not separately meaningful. Adjusted EPS for FY2024 of 3.51 is the figure shown as comparative in the Factsheet FY2025.

Margins

Revenue CAGR FY2021–FY2025: minus 6.7% (calculated). This overstates the organic decline because the FY2024 and FY2025 base excludes roughly €3.8–3.9 billion of coatings sales.

Commentary. Three things explain the path from €11.3 billion to €6.6 billion of EBITDA before special items. First, the 2022 European energy shock permanently raised Ludwigshafen's cost position; BASF responded by closing ammonia, caprolactam, TDI and adipic acid capacity. Second, global overcapacity in basic chemicals, much of it Chinese, compressed upstream margins from 2023 onward; Petrochemicals prices fell 10.0% in FY2025 alone. Third, currency turned against BASF in 2025, taking 3.0% off sales and €235 million off EBITDA before special items. Net income is a poor guide to operating performance in any of these years: 2022 was hit by Wintershall Dea's Russian write-offs, and 2025 was lifted by €1.3 billion of net special income in the equity result, mainly German federal guarantee reimbursements to Wintershall Dea for expropriated Russian assets. The gap between EPS of €1.82 and adjusted EPS of €2.24 in 2025, and the fall in adjusted EPS from €3.51, is the cleaner picture.

Balance sheet

Mid-2026 position (Half-Year Financial Report 2026). Cash and cash equivalents €7,796 million; noncurrent financial indebtedness €18,827 million; current financial indebtedness €6,177 million; equity €37,396 million; equity ratio 44.6%; net debt about €17.1 billion. The cash balance reflects the €5.8 billion Coatings inflow on June 30, 2026. BASF repaid about €1.25 billion of bonds and loans in the first half and planned €2.5 billion of repayments in the second half, including about €1.6 billion ahead of maturity (Q2 2026 presentation as reported by Investing.com).

Cash flow

Capital expenditure is derived as operating cash flow less free cash flow; BASF states €4,267 million for FY2025. Dividends paid are my calculation from the per-share dividend and share count, not the cash flow statement line.

Buybacks. A program of up to €3 billion launched in January 2022 was terminated in February 2023 after about €1.4 billion had been repurchased. A second program of up to €1.5 billion ran from November 2025 to June 2026; about €880 million had been bought by the April 30, 2026 AGM, and the Q2 2026 presentation describes the program as completed. A third program of up to €1.0 billion started August 3, 2026 and runs to April 2027; 5,025,589 shares had been bought by September 25, 2026 (BASF buyback interim report).

Commentary. Free cash flow bottomed at €748 million in 2024 at the peak of Zhanjiang spending, when capital expenditure of €6.2 billion consumed 89% of operating cash flow. In every year from 2021 to 2025 the dividend exceeded what 2024–2025 free cash flow could fund; the 2024 dividend cut to €2.25 was the acknowledgment. FY2025 operating cash flow fell €1.3 billion because rising precious-metal prices tied up cash in trading positions. First-half 2026 free cash flow was minus €1,564 million, the usual seasonal pattern worsened by higher raw-material prices inflating receivables and inventories.

Ratios

Net debt to EBITDA before special items (calculated): 2.59x at FY2024 and 2.80x at FY2025; on originally reported figures roughly 1.3x (FY2021), 1.5x (FY2022) and 2.2x (FY2023).

Management guidance for 2026 (as raised July 15, 2026).

First-half 2026 EBITDA before special items was €4,805 million, so the guidance implies €2.1–2.9 billion in the second half against €2.5 billion in the second half of 2025. Segment guidance from February 2026: considerable increases in Chemicals and Nutrition & Care, slight increase in Industrial Solutions, slight decreases in Materials and Agricultural Solutions, considerable decrease in Surface Technologies. In Q2 2026 Materials and Industrial Solutions beat consensus considerably while Chemicals and Surface Technologies missed.

Consensus. Vara consensus in July 2026: EBITDA before special items €7.3 billion and free cash flow €2.3 billion for 2026.

Bull case

1. Self-help is real and compounding. Cost savings reached a €2.0 billion run rate by June 2026 with €2.3 billion targeted by year-end, CoreShift targets a further cut of up to 20% in core fixed costs by 2029, and capex has fallen by almost half from the 2024 peak.

2. Sum-of-the-parts crystallization. Coatings was sold at about 13x EBITDA against a group multiple below 10x. Agricultural Solutions earns €2.1 billion of EBITDA; a pure-play multiple on a minority listing in 2027 would make the discount explicit.

3. Operating leverage into any recovery. Q2 2026 showed what happens when prices and volumes move together: EBITDA before special items up 54% on sales up 16%.

Bear case

1. The 2026 uplift is a supply shock, not a cycle turn. BASF's own outlook hinges on the Strait of Hormuz; a settlement that reopens supply would reverse price gains while chemical production growth is forecast at only 1.8%.

2. Cash is not following earnings. First-half 2026 free cash flow was minus €1.6 billion, and reaching even the low end of the €1.5–2.3 billion range needs a strong second half and working-capital release.

3. Capital allocation risk has returned. A takeover of Evonik at or above the reported €14 billion enterprise value would absorb the Coatings proceeds and more, in a company whose ROCE is 5.8%, and could jeopardize the single-A rating and buyback pace.

Catalysts and monitorables for the next 12 months.

• Q3 2026 results (late October 2026): second-half run rate, working capital, Chemicals margin.

• Capital Markets Day, November 24, 2026: updated 2028 targets, CoreShift detail, Agricultural Solutions equity story.

• Evonik: a revised proposal, a statement from RAG-Stiftung, or withdrawal.

• Middle East: any agreement on the Strait of Hormuz and the reaction of chemical prices.

• Agricultural Solutions: completion of the legal carve-out by early 2027 and the decision on IPO timing.

• Harbour Energy sell-down and second-half debt repayments of about €2.5 billion.

• Year-end cost run rate versus €2.3 billion and FY2026 free cash flow versus guidance.

• Zhanjiang utilization and its effect on Chemicals depreciation and emissions.

• PFAS docket developments.

Analyst verdict. BASF in October 2026 is a better-run company than it was two years ago and a more complicated investment than it was six months ago. The operational record under Kamieth is solid: cost targets were beaten and raised, Zhanjiang started up, capex was cut hard, Coatings was sold at a multiple the group itself does not command, and the balance sheet was repaired enough to pull buybacks forward by more than a year. The first guidance upgrade in years followed. Against that, the 2025 result was the fourth consecutive year of declining EBITDA before special items and a miss against thrice-lowered guidance, and the 2026 rebound owes much to a geopolitical supply shock that management openly says could reverse.

The equity case rests on three questions. First, whether core earnings can rise without help from disrupted supply; Chemicals lost money at the EBIT level in 2025 and missed consensus in the strong second quarter. Second, whether cash follows: free cash flow has not covered the dividend since 2023. Third, and newly, whether management will stay disciplined. The Evonik approach is strategically coherent, since additives and specialty polymers fit the core and overlap is limited, but it would redirect portfolio proceeds from shareholders to a seller whose anchor holder controls the outcome, at a time when BASF earns less than its cost of capital.

On balance the risk-reward is fair, not compelling, at roughly 8.6 times guided EBITDA. The share is supported by a 4.4% dividend yield, a live buyback and a dated catalyst in the agricultural listing. I would want evidence from the third-quarter cash flow and the November Capital Markets Day, and clarity on Evonik pricing, before treating the 2026 upgrade as the start of a durable recovery.